Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.04B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.56M
Average 1.66M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
Intrinsic Alpha fair value
Locked
Current Price
$16.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +230.7% (5yr)2 analysts |
| Revenue | N/A | N/A | +38.3% | +25.2% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | +230.5% (5yr)3 analysts |
| EBIT | N/A | N/A | N/A | +65.2% (5yr)3 analysts |
Analysis
Recent growth has been strongest in Revenue at +38.3% over three years. Forward estimates point to EPS at +230.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Ascendis Pharma A/S NASDAQ:ASND | $18.06B | $275.39 | Not rated | 24.5 | +22.15% |
Corcept Therapeutics Incorporated NASDAQ:CORT | $7.98B | $72.94 | Undervalued | 178.2 | -13.42% |
MBX Biosciences, Inc. Common Stock NASDAQ:MBX | $2.78B | $55.94 | Not rated | -22.0 | +97.60% |
Septerna, Inc. NASDAQ:SEPN | $2.03B | $42.60 | Undervalued | -43.6 | +64.91% |
Eton Pharmaceuticals, Inc. NASDAQ:ETON | $1.84B | $63.93 | Undervalued | -597.6 | +276.44% |
MannKind Corporation NASDAQ:MNKD | $1.33B | $4.13 | Overvalued | -50.3 | -20.52% |
GH Research PLC NASDAQ:GHRS | $1.31B | $19.10 | Not rated | -23.8 | +32.67% |
Spruce Biosciences, Inc. NASDAQ:SPRB | $124.47M | $43.31 | Not rated | -1.9 | -60.54% |
Continue the stock analysis
Jump to another research area for this company.